A promising new drug called baxdrostat may offer fresh hope for people living with both high blood pressure and chronic kidney disease.
Scientists say the medication not only lowers blood pressure but may also help slow damage to the kidneys, which is especially important because these two health problems are closely connected.
The findings come from a recent clinical trial and were published in the Journal of the American Society of Nephrology.
Researchers believe the drug could become an important new treatment option for people whose blood pressure remains dangerously high even after taking several existing medications.
High blood pressure, also called hypertension, is one of the leading causes of chronic kidney disease around the world.
Over time, high pressure inside blood vessels can damage the tiny filtering units inside the kidneys. As kidney function worsens, blood pressure often rises even more, creating a harmful cycle that becomes difficult to control.
Chronic kidney disease, often shortened to CKD, affects millions of people worldwide. In the United States alone, experts estimate that around one in seven adults has some form of kidney disease. In many cases, kidney damage cannot be reversed once it becomes severe.
People with both kidney disease and uncontrolled high blood pressure face a much higher risk of heart attacks, strokes, heart failure, and kidney failure. Because of this, doctors have been searching for treatments that can target both conditions together.
The new drug, baxdrostat, works in a different way from many current blood pressure medications. It blocks the body from producing a hormone called aldosterone. This hormone helps control salt and fluid levels in the body, but too much aldosterone can raise blood pressure and contribute to kidney damage over time.
Unlike older medications that mainly block the hormone’s effects after it is produced, baxdrostat stops the hormone from being made in the first place. Researchers believe this approach may provide stronger protection for both blood vessels and kidneys.
The study involved nearly 200 people who had both chronic kidney disease and uncontrolled high blood pressure. Many participants were already taking standard medications, yet their blood pressure still remained too high. Researchers added baxdrostat to their existing treatment plans and followed the patients for about six months.
The results were encouraging. On average, people taking baxdrostat experienced a larger drop in blood pressure compared with those receiving standard treatment alone. Researchers reported that systolic blood pressure fell by about 8.1 mm Hg more in the baxdrostat group than in the control group.
Even more interesting were the results related to kidney health. Scientists measured levels of a protein called albumin in the urine. High amounts of albumin often signal that the kidneys are damaged and leaking protein. Lower levels usually suggest healthier kidney function.
After six months of treatment, patients taking baxdrostat had less than half the amount of urine albumin compared with people receiving standard care alone. Researchers said this finding suggests the drug may help slow the progression of kidney disease.
Doctors involved in the study described the findings as highly promising. Some experts even called the medication a possible “game changer” for people with treatment-resistant hypertension, which means blood pressure that stays high despite taking multiple medications.
Researchers also said baxdrostat appeared generally safe and well tolerated during the trial. However, like all medications, it may still cause side effects, and scientists say larger studies are still needed to fully understand its long-term safety.
Several additional clinical trials are already underway to test baxdrostat in larger groups of patients and to study its effects on kidney disease, heart health, and hypertension more closely.
The research reflects a growing shift in medicine toward treatments that target the underlying causes of disease rather than only treating symptoms. By lowering aldosterone production directly, baxdrostat may help break the damaging cycle between high blood pressure and kidney disease.
Experts caution that the drug is still being studied and may not be appropriate for everyone. People with high blood pressure or kidney disease should always speak with their doctors before changing medications or treatment plans.
Still, the early findings offer hope for millions of people struggling with these serious health conditions. If future studies continue to show strong results, baxdrostat could become an important new tool for protecting both the heart and kidneys at the same time.
If you care about high blood pressure, please read studies about unhealthy habits that may increase high blood pressure risk, and drinking green tea could help lower blood pressure.
For more information about high blood pressure, please see recent studies about what to eat or to avoid for high blood pressure, and 12 foods that lower blood pressure.
The study was published in the Journal of the American Society of Nephrology.
